Vascular Immunotargeting: Take the Highway to the First Exit
Vladimir R. Muzykantov, Jacob S. Brenner – 2 August 2018
Reply
Norah A. Terrault, Robert S. Brown, Anna SF Lok, John B Wong, Natalie H Bzowej, Kyong‐Mi Chang, Jessica P Hwang, Maureen M Jonas, Brian J McMahon – 2 August 2018
A New Concept: Pre‐HCC Disease
Yao Yang, Yuemin Feng, Xinya Zhao, Le Wang, Xiaoyu Xie, Jie Li, Mindie H. Nguyen, Qiang Zhu – 2 August 2018
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, Marlyn Mayo – 2 August 2018
Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases
Keith D. Lindor, Christopher L. Bowlus, James Boyer, Cynthia Levy, Marlyn Mayo – 2 August 2018
The Efficacy of Tenofivir to Prevent Perinatal Transmission in Chronic Hepatitis BMothers. AClinical Perspective
Ghassan Mubarak, Richard Ferstenberg – 2 August 2018
Diabetes, Liver Cancer, and Cirrhosis: What Next?
Hannele Yki‐Järvinen, Panu K. Luukkonen – 2 August 2018
Mailed Outreach Invitations Significantly Improve HCC Surveillance Rates in Patients With Cirrhosis: A Randomized Clinical Trial
Amit G. Singal, Jasmin A. Tiro, Caitlin C. Murphy, Jorge A. Marrero, Katharine McCallister, Hannah Fullington, Caroline Mejias, Akbar K. Waljee, Wendy Pechero Bishop, Noel O. Santini, Ethan A. Halm – 2 August 2018 – Hepatocellular carcinoma (HCC) surveillance is associated with early tumor detection and improved survival in patients with cirrhosis; however, effectiveness is limited by underuse. We compared the effectiveness of mailed outreach and patient navigation strategies to increase HCC surveillance in a racially diverse cohort of patients with cirrhosis.
A Novel Mechanism of Starvation‐Stimulated Hepatic Autophagy: Calcium‐Induced O‐GlcNAc‐Dependent Signaling
Yang Shen, Mark J. Czaja – 2 August 2018
Patient‐Reported Outcomes and the Economic Effects of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: The Value Proposition
Zobair M. Younossi – 2 August 2018 – Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) can progress to cirrhosis, hepatocellular carcinoma (HCC), death, or liver transplantation. NASH has also been associated with impaired health‐related quality of life and poses a significant economic burden.